Nanograb
Deliver genes to any cell with AI
What they do
Safe, targeted delivery of genetic medicines to specific cells and tissues remains difficult with existing gene therapy vectors.
An AI-driven platform designs targeted non-viral gene therapy vectors by combining small peptide binders with nanoparticles to deliver genes to specific cells at scale.
Biopharma companies and gene therapy developers creating genetic medicines needing targeted, scalable delivery vectors.
Founders
Co-founder and CEO of Nanograb. PhD in Computational Biophysics from Imperial College London. Experienced in molecular simulations and building software for scientists. First software hire at Fabricnano
Co-founder of Nanograb. M.Eng Biomaterials and Tissue Engineering at Imperial College London. Biomedical engineering experience developing biosensors using aptamers, and a drug delivery device for hypertension management.
Cofounder and in silico lead at Nanograb; Imperial College PhD (dropout); Fascinated by all things compute and physics... all in the name of figuring out real life things! Otherwise, I love singing and music in general. Fun fact: I was in an a cappella group for 5 years :)
Company timeline
- Founded2023
- YC batchSummer 2023
- StatusActive
- Team size5 people
- LocationSan Francisco, CA, USA
Similar startups
